Press releases

1 2 3 28

BD Advances Technology to Create Endovascular AV Fistulas for Chronic Kidney Disease Patients Who Require Hemodialysis

Feb 13, 2019

BD WavelinQ 4F EndoAVF System Receives 510(k) Clearance from U.S. Food and Drug Administration

BD Announces Results for 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

Feb 5, 2019

BD Announces Results for 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

BD Launches Ergonomic Pen Needle Technology to Help Optimize Injection Technique

Jan 24, 2019

BD Nano™ Second Generation Pen Needle Receives 510(k) Clearance from U.S. Food and Drug Administration

BD Completes Molecular Portfolio For GI Infection With New Viral Panel

Dec 20, 2018

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of its BD MAX enteric viral panel, a molecular diagnostic test for the direct qualitative detection and differentiation of enteric viral pathogens that cause viral gastroenteritis.

BD Announces completion of enterprise level cybersecurity assessment from UL

Dec 11, 2018

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL.

BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversion

Nov 29, 2018

Learn how advanced analytics can help combat a critical component of the opioid epidemic at the #ASHP18 Midyear Meeting

New Diagnostic Test Helps Hospitals More Quickly Identify and Treat Emerging Antibiotic-Resistant Bacteria

Nov 13, 2018

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of the BD Phoenix CPO detect test, which will allow hospitals to identify infections caused by carbapenemase-producing organisms (CPOs).

BD Announces Results for 2018 Fourth Fiscal Quarter and Full Year; Provides Fiscal 2019 Guidance

Nov 6, 2018

BD Announces Results for 2018 Fourth Fiscal Quarter and Full Year; Provides Fiscal 2019 Guidance

BD MedMined Earns Meaningful Use Stage 2 Certification for Antimicrobial Use and Resistance Reporting

Oct 29, 2018

BD MedMined Earns Meaningful Use Stage 2 Certification for Antimicrobial Use and Resistance Reporting

BD to Invest $200 Million in Nebraska Operations Creating 300 More Jobs

Oct 23, 2018

BD to Invest $200 Million in Nebraska Operations Creating 300 More Jobs

1 2 3 28